July 9, 2019 • WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)

WindMIL Therapeutics (WindMIL) and the University of Michigan Rogel Cancer Center today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with head and neck squamous cell carcinoma (HNSCC).

June 25, 2019 • WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, announced today that it has been cleared by the U.S. Food and Drug Administration (FDA) to proceed with its Phase 2 study of MILs as a potential treatment for patients with non-small cell lung cancer (NSCLC) who have progressed on an anti-PD-1 containing […]

April 26, 2019 • Endpoints: Peer Review: Don Hayden commits to CEO role at WindMIL; X4 nabs new CMO Lynne Kelley from Histogenics exile

Since leaving a 25-year career and the president of global pharmaceuticals title at Bristol-Myers Squibb in 2005, Don Hayden has kept himself busy as a consultant and adviser to biopharma companies, sometimes juggling seven or eight board appointments. But after a few months as interim CEO of WindMIL Therapeutics, he’s ready to “substantially pull back” on all those commitments as he transitions to a full-time role.

April 25, 2019 • WindMIL Therapeutics Appoints Donald J. Hayden, Jr., as CEO

WindMIL Therapeutics has announced the appointment of Donald J. Hayden, Jr., as CEO.

April 25, 2019 • Philadelphia Business Journal: Former Bristol-Myers Squibb executive named CEO of immunotherapy company

After spending the past four months as interim CEO of WindMIL Therapeutics, former Bristol-Myers Squibb executive Donald J. Hayden Jr. has accepted the position on a permanent basis.

April 25, 2019 • FierceBiotech: WindMIL Therapeutics interim CEO Hayden steps up to the plate

When Donald Hayden, a 25-year veteran of Bristol-Myers Squibb, joined WindMIL Therapeutics as its executive chairman, he figured he would steer the ship until the company’s board picked a permanent CEO. But as he got to know the company and the marrow-infiltrating lymphocytes from which it takes its name, he “threw his hat into the […]

April 25, 2019 • BioCentury: Management tracks: Canbridge, Averum, WindMIL

Cancer immunotherapy company WindMIL Therapeutics Inc. (Baltimore, Md.) said Chairman and interim CEO Donald Hayden will become the permanent CEO.

April 19, 2019 • FierceBiotech: Chutes & Ladders—Gilman buckles in as Arrakis raises $75M, while Wotton takes over at Obsidian

WindMIL Therapeutics, developers of marrow-infiltrating lymphocytes for cancer, has established new leadership positions, promoting Chief Scientific Officer Kimberly Noonan to executive VP and CSO, and operations VP Patrick Dougherty to VP of planning and operations. Noonan also serves as a scientific co-founder of WindMIL.

April 17, 2019 • WindMIL Therapeutics Announces Promotions to Newly Created Leadership Roles as Part of Continued Growth

WindMIL Therapeutics has announced the promotions of Kimberly Noonan, PhD, MPH, to Executive Vice President and Chief Scientific Officer and Patrick Dougherty to Vice President, Planning and Operations. Noonan previously served as Chief Scientific Officer and Dougherty as Vice President, Operations.

March 29, 2019 • Endpoints: Sunao Manabe takes top job at Daiichi Sankyo in wake of AstraZeneca deal; CAR-T player Celyad promotes Filippo Petti to CEO

WindMIL Therapeutics has tapped Sanjin Zvonić, a seasoned exec who most recently led Progenitor Cell Therapy’s integration into Hitachi, to lead its processes and manufacturing.